Announced
Completed
Financials
Sources
Tags
Medical Supplies
Acquisition
Majority
Health Care Supplies
Single Bidder
United States
Health Care Services
Friendly
Public
Domestic
Completed
Synopsis
Charles River Laboratories, which provides clinical tests and drug development services, completed the acquisition of HemaCare, which provides customized delivery of biological blood products and services, for $380m. “HemaCare advances the development of life-saving cell therapies through the use of its high-quality cellular products that represent critical inputs to these therapeutics. The addition of HemaCare’s innovative cell therapy products and services to our integrated, early-stage solutions will create a unique, go-to partner for clients to work with Charles River across a comprehensive cell therapy portfolio from idea to novel therapeutic,” James C. Foster, Charles River Laboratories Chairman, President, and Chief Executive Officer.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.